ARCPOINT REPORTS Q1 2025 FINANCIAL RESULTS

ARCpoint Inc. reported Q1 2025 financial results, showing a decrease in revenue to $0.18 million from $1.61 million year-over-year, primarily due to the CRESSO joint venture, which deconsolidated franchise operations. Net loss decreased to $0.62 million from $1.5 million, driven by cost reductions and a gain from the disposal of ABH Greenville. The company is implementing temporary compensation and professional services cost reductions of approximately $57,000 per month to manage finances while focusing on growing its MyARCpointLabs platform.

Analysis

ARCpoint Inc.'s Q1 2025 financial results highlight a significant transformation following the CRESSO joint venture established in August 2024, which involved combining its franchise operations with Any Lab Test Now. This restructuring led to a substantial decrease in reported total revenues to $0.18 million, down from $1.61 million in Q1 2024, as franchise revenues are no longer consolidated and ARCpoint's 29.5% interest in CRESSO is accounted for via the equity method. Despite this revenue decline, the company's net loss improved to $0.62 million from $1.5 million year-over-year, benefiting from reduced operating costs stemming from the CRESSO transaction, a $0.3 million gain on the disposal of its ABH Greenville interest for $360,000 cash, and a $0.2 million share of income from CRESSO. To further manage its finances, ARCpoint enacted temporary monthly cost reductions of approximately USD$57,000 in compensation and professional services starting mid-April 2025. However, operating cash flow remained negative at $0.9 million, albeit an improvement from negative $1.3 million in the prior year's quarter, and both EBITDA (negative $0.4 million) and Adjusted EBITDA (negative $0.6 million) also showed year-over-year improvement while remaining negative. A critical point of concern is the company's low cash position, which stood at approximately US$0.23 million as of March 31, 2025. Management is focused on driving revenue growth through increased adoption of its MyARCpointLabs (MAPL) technology platform, which has been selected as the system of choice for the CRESSO franchise network.

Key Decisions for Investors

• Investors should critically assess ARCpoint's near-term liquidity, given its US$0.23 million cash balance and negative $0.9 million Q1 operating cash flow, and monitor for potential financing needs or further asset sales.
• The primary focus should be on tracking the adoption and revenue generation capabilities of the MyARCpointLabs (MAPL) platform, as its success is crucial for future growth and for leveraging the company's 29.5% stake in the CRESSO franchise network.
• Evaluate the progress of the strategic shift towards a technology and equity-holding model, particularly the financial contribution from CRESSO and whether temporary cost reductions can bridge the gap to sustainable positive cash flow.